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Objectives: Understanding the relationship between human papillomavirus (HPV) knowledge
and vaccination behavior is important to inform public health interventions, yet few validated
HPV knowledge scales exist. This study describes development of the Human Papillomavirus
Knowledge Questionnaire (HPV-KQ) and its validation with parents residing in the southern
United States (US). Methods: Drawing on previously published measures, we developed the
13-item HPV-KQ and administered the scale via Web-based survey to parents (N=1105) of
adolescents ages 9 to 17 years. Dimensionality, internal consistency, model fit, and predictive
validity were assessed. Results: The scale was bidimensional. One factor captured general HPV
knowledge, and the second factor captured perceptions of gender differences in HPV infection
and vaccine recommendations. The 13-item scale and 2-factor solution displayed strong internal
consistency and good model fit. Parents of vaccinated adolescents scored higher on the 13-item
HPV-KQ (Mean = 8.56) than parents of unvaccinated adolescents (Mean = 6.43) (p < .001). In
regression models, controlling for key covariates, parents’ performance on the HPV-KQ predicted
adolescent HPV vaccination (p < .001). Conclusions: Evaluation indicates the HPV-KQ is a reliable
and valid tool for measuring knowledge of HPV and the HPV vaccine among parents residing in
the southern US. We recommend further efforts to validate the scale with other populations.
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Am J Health Behav.™ 2021;45(5):810-827
DOI: https://doi.org/10.5993/AJHB.45.5.2

H

uman papillomavirus (HPV) is the most
common sexually transmitted infection,
affecting almost every unvaccinated adult

over the course of their life.1 Currently, an estimated
79 million individuals in the United States (US)
have active HPV infection, and 14 million new
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the US),17,18 and small sample sizes in psychometric
analyses.17,19
Reliable and valid measures for assessing HPV
knowledge are important to identify gaps in
knowledge, as well as knowledge disparities across
groups, so as to understand changes in knowledge
over time, and to investigate the role that knowledge
plays in vaccination decision-making. Current
literature indicates that parental awareness and
knowledge of HPV is associated with vaccination
decision-making and adolescent vaccination status.21-25
For instance, Allen et al22 reported higher levels of
HPV and HPV vaccine-related knowledge among
parents with vaccinated adolescents or those with
the intention to vaccinate, compared to parents
who decided against vaccinating their adolescents.
Mansfield et al24 also found that parents with higher
HPV knowledge were significantly more likely to
report an intention to vaccinate their daughters.
Although some studies failed to identify a relationship
between parental HPV knowledge and adolescents’
vaccination status,23,26 those studies were notable
for small sample size (ie, < 200 parents)23,26 and the
inclusion of parents of male adolescents only.23 In
addition, HPV vaccination promotion campaigns
recently have adopted a strong emphasis on ‘HPV
vaccination as cancer prevention’ in advertising
and messaging campaigns and now emphasize the
importance of on-time initiation of vaccination for
boys and girls. Multiple existing HPV knowledge
scales reflect outdated vaccine information (eg,
3-dose regimens, initial approval for girls only),
and were developed prior to approval of the
9-valent HPV vaccine that prevents HPV infections
that cause cervical, anogenital, and head and neck
cancers.27
Given the limitations of existing scales, we
identified the need for an updated, brief HPV
knowledge scale and undertook the development
of the Human Papillomavirus – Knowledge
Questionnaire (HPV-KQ), an instrument designed
to assess HPV and HPV vaccine-related knowledge.
In this study, we describe the development of this
scale and present an evaluation of its psychometric
properties. Furthermore, we investigate knowledge
differences on the HPV-KQ across parents with
vaccinated versus unvaccinated adolescents. We
also assess the predictive validity of the HPV-KQ
by examining associations between parents’ performance on the HPV-KQ and the HPV vaccination
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infections occur annually.1 Whereas over 100
different types of human papillomaviruses are
known, 14 types are considered high-risk due to
their oncogenic potential.2 HPV infections are
responsible for 44,000 cancer cases every year in
the US, including nearly all cases of cervical cancer,
as well as cancers of the vulva, vagina, penis, anus,
and oropharynx.3,4 Among HPV-attributable cancers,
43% of cases occur in men.3
In 2006, a safe and effective HPV vaccine was
approved by the US Food and Drug Administration
(FDA) for adolescent girls.5 Approval for adolescent
boys followed in 2011, with the latest vaccine
protecting against 9 different HPV types6 and
preventing an estimated 92% of HPV-attributable
cancers.7 Currently, the Advisory Committee on
Immunization Practices (ACIP) recommends that
immunocompetent adolescents initiate a 2-dose
series of HPV vaccination at ages 11 or 12 years;
adolescents who initiate at or after 15 years of age
require 3 doses, with “catch-up vaccination” recommended through 26 years of age.8 Most recently,
ACIP has endorsed shared clinical decision-making
when considering HPV vaccination for unvaccinated
individuals ages 27 through 45 years.8,9
The National HPV Vaccination Roundtable and
Healthy People 2030 have endorsed a national goal
of increasing the proportion of adolescents (ie, ages
13 through 15 years) who have received all recommended doses of the HPV vaccine to 80%.10,11
However, currently 72% of US adolescents have
had at least one dose of the HPV vaccine, and only
54% are fully vaccinated against HPV.12 Existing
research suggests that US adolescents and their
parents/caregivers continue to have limited knowledge of HPV and the HPV vaccine.13,14 Increasing
knowledge of the risks associated with HPV
infection and the safety and efficacy of the HPV
vaccine are important first steps to build confidence
in vaccination and increase uptake among US
adolescents.15,16
Several validated scales to assess parental knowledge of HPV have been developed.17-20 Limitations
of existing knowledge scales include the length of
the instrument or use of separate scales for general
and vaccine-specific HPV knowledge,18-20 limited
inclusion of items addressing male vaccination and
male HPV-associated cancers, validation with
subpopulations only (eg, Canadian parents of
boys; African-American mothers of daughters in
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status of their adolescents, while controlling for
known correlates of HPV vaccination. We hypothesized that parents of vaccinated adolescents would
score higher on the HPV-KQ than parents of
unvaccinated adolescents and that parents’ scores
on the HPV-KQ would predict vaccination status
of their adolescent.
METHODS
Background
Data were collected as part of a larger study
(U01IP001095) funded by the US Centers for
Disease Control and Prevention (CDC) that aimed
to investigate rural-urban HPV disparities in the
US and develop a responsive intervention to increase
adolescent HPV vaccination.
Development of the 13-item HPV-KQ
Initially, members of the study team, consisting
of experts from a variety of health-related disciplines
(eg, pediatrics, public health, health psychology,
cancer, and health disparities research) reviewed
existing HPV knowledge scales.17-21,28,29 Team
members identified key HPV-related information
that was commonly represented in existing scales
(eg, causes cervical cancer, sexually transmitted,

highly prevalent, can be asymptomatic, affects men
and women). They then identified other important
HPV-related information that was rarely or never
represented (eg, causes other cancers, including
head and neck cancers; causes cancers in men;
vaccination recommended for boys and girls;
vaccination requires more than one dose).
The team then developed a 13-item true/false
scale (Box 1) to measure HPV- and HPV vaccine-
related knowledge. Final decisions on item selection
and wording were made through an iterative
consensus building process and prioritized the
creation of a scale that was brief, contained items
about both HPV and HPV vaccination, and
addressed HPV’s impact on both males and females.
Four items (ie, items 1, 2, 7, 13) were modified
from existing scales to improve wording or to
enhance the accuracy of the statement. For instance,
one item, “HPV can be passed on during sexual
intercourse,”20 was modified to read “HPV is transmitted through sex.” This is important because
HPV can be transmitted through non-intercourse
sexual acts (eg, anal and oral sex), as illustrated by
increases HPV-associated anal and oropharyngeal
cancers.30 Replacing “intercourse” with the more
general term of “sex” is also important to create
a more inclusive scale (ie, recognizing that HPV

Box 1. The 13-item Human Papillomavirus Knowledge Questionnaire (HPV-KQ)
Human Papillomavirus Knowledge Questionnaire (HPV-KQ)
Directions: For each statement below, please select “True”, “False”, or “Don’t know”. If you have never heard of HPV, please select
“Don’t know” for the statements below.
True

False

Don’t Know

1. Only women can gel infected with HPV*

T

F

DK

2. HPV can cause cervical cancer in women

T

F

DK

3. HPV can cause cancer in areas such as the head and neck

T

F

DK

4. HPV causes cancer in women only*

T

F

DK

5. HPV can cause genital warts

T

F

DK

6. A person could have HPV for many years without knowing it

T

F

DK

7. HPV is transmitted through sex

T

F

DK

8. Most people infected with HPV have visible signs or symptoms of the infection*

T

F

DK

9. A person’s chances of getting HPV increase with the number of sexual partners they have

T

F

DK

10. Nearly all sexually active people will contract HPV at some point

T

F

DK

11. The HPV vaccine is only recommended for girls*

T

F

DK

12. Full protection against HPV requires more than 1 dose of the vaccine

T

F

DK

13. The HPV vaccine is most effective if given to people who have not yet started having sex

T

F

DK

Note: “Indicated reverse scored item.
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for males aged 9-26 years”). The team considered
knowledge on the need for and recommendations
on adolescent male vaccination to be salient information for an HPV knowledge scale because of the
large body of literature that has shown that parents
of male adolescents and male adolescents themselves
are less likely to be knowledgeable about HPV
vaccination or to receive recommendations for
vaccination.32-34 Thus, item 11 was developed (“The
HPV vaccine is only recommended for girls” [False
item]). Finally, given changing recommendations
on required doses of the HPV vaccine (ie, 2 doses
if HPV vaccination begins at < 15 years of age; 3
doses if HPV vaccination begins at ≥ 15 years of
age), a new item was developed (ie, item 12; “Full
protection against HPV requires more than 1 dose
of the vaccine”).
Thus, the HPV-KQ includes 13 items that address
key HPV constructs (ie, transmission, sequelae,
prevention) and includes items on male vaccination
and male HPV-associated cancers that are not
well-represented in existing scales. Following
development, the HPV-KQ was tested for readability,
yielding a Flesch Reading Ease score of 72.6 (ie,
fairly easy to read) and a Flesch-Kincaid Grade
Level score of 5.8. The HPV-KQ was programmed
for delivery via the QualtricsXM survey platform
and pilot-tested for acceptability and clarity with a
convenience sample of 23 parents of children and
adolescents. No major concerns were identified
by pilot-study participants, and thus, the 13-item
scale was finalized and deployed for the current
study. Pilot-test respondents were not included in
the study sample or data analysis.
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transmission also occurs during sex between men
and during sex between women).
Five items (ie, items 5, 6, 8, 9, 10) were directly
replicated from existing scales. Specifically, item
5 (“HPV can cause genital warts”) has been used
verbatim in previous scales.20,21 Item 6 (“A person
could have HPV for many years without knowing
it”) was directly replicated from Waller’s scale20
because the item remains important and aligns
with current scientific evidence. Item 8 (“Most
people infected with HPV have visible signs or
symptoms of the infection”), item 9 (“A person’s
chances of getting HPV increase with the number
of sexual partners they have”), and Item 10 (“Nearly
all sexually active people will contract HPV at
some point”) were directly replicated from Kasymova
et al,28 although similar items have appeared in at
least 2 other scales.18,20
At least one prior scale29 includes an item about
HPV’s causal role in head and neck cancers; the
expert team believed a standalone item about head
and neck cancers was needed, given the dramatic rise
in oropharyngeal cancers due to HPV.30,31, Thus a
similar item was created for the HPV-KQ (ie, item 3;
“HPV can cause cancer in areas such as the head
and neck”). The team also created an item to assess
whether individuals understood that HPV-caused
cancers occur in both men and women (item 4;
“HPV causes cancer in women only” [False item]).
This information was considered important to
include because of the identified knowledge gap
concerning HPV-related cancers in men.31-33
Similarly, the team identified knowledge about
pan-gender recommendations for HPV vaccination
to be salient, given previous literature showing that
both adolescents and adults in the US often falsely
believe that HPV vaccination is recommended only
for girls or young women.32,33 In addition, previous
research has shown that healthcare providers are less
likely to recommend the HPV vaccine to parents
of male adolescents,34,35 despite recommendations
from ACIP and American Academy of Pediatrics
(AAP) that routine HPV vaccination be initiated at
age 11 or 12 years for males, with vaccination able
to be given starting at age 9.36-38 No existing scales
were identified that have items about the 2011
recommendation for HPV vaccination among boys
in the US, although Perez et al21 developed a similar
item for a Canadian sample (“The HPV vaccine
is approved and recommended by Health Canada

Study Design and Sample
From December 2019 to January 2020 we recruited
parents and legal guardians of adolescents, ages 9
to 17 years, through the Ipsos KnowledgePanel®, a
nationally representative online research panel with
members recruited through address-based probability
sampling methods. The KnowledgePanel® includes
both US residents with Internet access and those
without. Internet access and a digital device are
provided to participating members without Internet
access to reduce the chances of under-sampling in
this group. Because the parent study was focused
on HPV vaccination in the southern US, the current
study included KnowledgePanel® members residing
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in southern states, as defined by the US Department
of Health and Human Services (HHS) as HHS
Region 4 (Alabama, Florida, Georgia, Kentucky,
Mississippi, North Carolina, South Carolina,
Tennessee) and HHS Region 6 (Arkansas, Louisiana,
New Mexico, Oklahoma, Texas). Other eligibility
criteria included: (1) having English proficiency,
(2) being ≥ 18 years of age, and (3) being a parent or
legal guardian of an adolescent aged 9 to 17 years.
A total of 2262 parents/guardians from the
KnowledgePanel® were contacted about the study
for recruitment, and 1250 (55.3%) opted into the
survey. We excluded 71 ineligible respondents (ie,
who did not meet inclusion criteria); an additional
74 respondents failed to complete the survey. This
yielded a total sample size of 1105 parents of
adolescents and a cooperation rate of 48.9%.
Procedure
We sent eligible members of the KnowledgePanel®
information about the study and an electronic link
to the survey. Parents and legal guardians (henceforth
referred to collectively as ‘parents’) were able to
complete the self-administered Web-based survey
on the platform of their choice. The introduction to
the survey contained a description of the research
study and an implied consent script. In addition
to the HPV-KQ, the survey also assessed vaccination-
related behaviors and experiences. The survey took
a median of 10 minutes to complete. Recruitment
of parents continued until the target sample size
of 1000 was reached. This target sample size was
based on the availability of eligible KnowledgePanel®
households in the 13 states and anticipated
response rates.
Measures
Socio-demographic characteristics. Parents’ socio-
demographic data were provided by Ipsos, (ie,
measured at recruitment into the KnowledgePanel®
and updated annually) including age, race/ethnicity,
highest level of education, gender, income level,
current employment status, marital status, and
household size. Zip codes were used to classify
participants as rural or urban based on Rural-Urban
Commuting Area (RUCA) codes, with RUCA ≥ 4
categorized as rural.39 Parents reported on key
socio-demographic characteristics of their adolescent,
including the adolescent’s age, gender, school
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setting (ie, public, private, online, homeschool),
and health insurance coverage (ie, presence and
type of insurance).
HPV-KQ. Participants responded to HPV-KQ
items by selecting “true,” “false,” or “I don’t know.”
A total knowledge score (possible range = 0-13)
was created for each participant by summing their
correct responses across the 13 items. Incorrect
responses and responses of “I don’t know” were
assigned a score of 0.
Adolescent HPV vaccination status and other
relevant healthcare variables. To examine the
relationship between parental knowledge and
adolescent vaccination status (ie, to assess the
predictive validity of the HPV-KQ), parents
were asked whether their adolescent had received
at least one dose of the HPV vaccine (“yes” vs
“no/I don’t know”). Parents also reported on several
other healthcare-related variables that were used as
covariates in later analyses (eg, how long it took
to travel to the place their adolescent most often
received healthcare, whether their adolescent had
received a healthcare visit in the past year, and
whether a provider had ever recommended the
HPV vaccine for their adolescent.)
Data Analysis
We analyzed the data using SAS 9.4 (SAS Institute,
Cary, NC). To correct for sampling biases due to
nonresponse and/or incomplete coverage of the
Web-based panel, we used survey weights provided
by Ipsos to calibrate data to be representative of the
target population (ie, parents of adolescents ages
9-17 years from 13 southern states).
We generated descriptive statistics for the total
sample of parents (N=1105), for parents with
vaccinated adolescents (≥ 1 dose of the HPV
vaccine; N=363), and for parents with unvaccinated
adolescents (N=742). We used chi-square and
Student’s t-test to examine group differences between
parents of vaccinated versus unvaccinated adolescents.
To investigate the structure of the HPV-KQ, we
used a randomization procedure to split the total
sample (N=1105) into 2 random subsamples.
We made no a priori hypotheses about underlying
factors and conducted exploratory factor analysis
(EFA) using principal component analysis with
varimax rotation on the HPV-KQ data from the
first randomly generated subsample (N=551).40
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We retained items with loadings larger than 0.45.
A confirmatory factor analysis (CFA) with data
from the second randomly-generated subsample
(N=554) was used to confirm the factor solution
that emerged from the EFA. To investigate model
fit, indices were compared to recommended
thresholds.41-43 We calculated Cronbach’s alpha to
measure internal consistency of the full 13-item
HPV-KQ and of the derived factor solution; alphas
between 0.80 and 0.95 were considered evidence
of strong internal consistency.44
To explore the predictive validity of the scale, we
used Student’s t-test to compare the performance
of parents of vaccinated versus unvaccinated
adolescents on the HPV-KQ. Specifically, we
compared parents’ responses on each of the 13
individual items and parents’ total knowledge
scores for the full 13-item scale and the derived
factor solution. To assess predictive validity further,
we used weighted multivariable logistic regression
to determine whether parents’ HPV knowledge, as
measured by the HPV-KQ, predicted adolescent
vaccine uptake (ie, ≥ 1 dose of the HPV vaccine).
In other words, we analyzed whether higher parent
scores on the 13-item scale and the derived factor
solution were associated with increased odds that
their adolescent was vaccinated against HPV.
Models were adjusted for parental and adolescent
demographic factors that were chosen from those
independently associated with the outcome variable
(ie, adolescent vaccine uptake) using stepwise selection procedures, with inclusion criteria of p < .05.
Data were clustered at the state level to account for
error correlation within states. We used odds ratios
and 95% confidence intervals to describe the extent
to which variation in parents’ knowledge was associated with adolescents’ vaccination status. Because
provider recommendation is a robust predictor of
HPV vaccine uptake,45-50 we estimated separate
models for parents who had received a provider
recommendation for HPV vaccination (N=593)
and parents who had not received a provider
recommendation for HPV vaccination (N=510).
In all analyses, p values < .05 were considered to be
statistically significant.

well as group differences between parents of vaccinated
versus unvaccinated adolescents. Parents’ mean age
was 42.7 years (SD = 8.1); parents of vaccinated
adolescents were significantly older than parents
of unvaccinated adolescents (p < .001). A total of
42.2% of the sample were fathers. Gender of the
parent was associated with adolescent vaccination
status, with more mothers reporting HPV vaccination among their adolescents than fathers (p = .045).
The diverse sample included 25.5% who were
Hispanic, 16.7% who were non-Hispanic black or
African-American, 51.7% who were non-Hispanic
white, and 6.2% who identified as a different
non-Hispanic race/ethnicity.
About one out of five (19.4%) participants resided
in a rural area. Most parents were married (80.4%),
with a mean household size of 4.2 members
(SD = 1.4). Most parents (59.0%) did not possess
a college degree. There was a statistically significant
difference in vaccination status by child’s age, with
parents of older adolescents more likely to report
that their child had been vaccinated against HPV
(p < .001). There was no statistically significant
difference in vaccination status by gender of the
adolescent (p = .49) or with respect to health
insurance coverage (p = .11). Parents who reported
that a healthcare provider had recommended HPV
vaccination were significantly more likely to have a
vaccinated adolescent (p < .001).

RESULTS
Table 1 summarizes key socio-demographic and
healthcare-related characteristics of the sample, as

Factor Analysis and Reliability Measures
Initially, dimensionality of the HPV-KQ was
examined with data from 551 participants. Tables 2
shows the results of the EFA. The rotated solution
yielded 2 factors, with relatively strong item loadings
(> .45).40,41 Factor 1 included 7 items (items 2, 5, 6,
7, 8, 9, 13) and captured 83.8% of total variance.
This factor appeared to capture general knowledge
of HPV. It included items such as “HPV can cause
genital warts,” “HPV is transmitted through sex,”
and “A person could have HPV for many years
without knowing it.” Factor 2 included 3 items
(items 1, 4, 11) and captured 16.2% of the variance.
This factor appeared to capture gender-related
aspects of HPV knowledge. Items that loaded onto
Factor 2 were: “Only women can get infected with
HPV” (False), “HPV causes cancer in women
only” (False), and “The HPV vaccine is only
recommended for girls” (False). Three items (items
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Table 1
Socio-demographic and Healthcare-related Characteristics of Total Study Sample (N=1105)
and by Child’s HPV Vaccination Status
Variable

Level

Total sample
(N=1105)

HPV
vaccinatedchild
(N=363)

HPV
un-vaccinated
child

p-value

(N=742)

CHARACTERISTICS OF PARENT
Age (M [SD])
Gender (parent)
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Race and ethnicity

42.69 (8.14)

Marital status

466 (42.17)

138 (37.94)

328 (44.28)

Female

638 (57.73)

225 (62.06)

413 (55.72)

Non-Hispanic black or
African-American

184 (16.65)

59 (16.14)

125 (16.84)

Non-Hispanic white

571 (51.67)

184 (50.74)

387 (52.11)

69 (6.24)

24 (6.65)

45 (6.01)

Hispanic

282 (25.52)

96 (26.47)

186 (25.04)

Urban

891 (80.63)

304 (83.65)

587 (79.07)

Rural

214 (19.37)

59 (16.35)

155 (20.93)

Married/Living with Partner

888 (80.36)

297 (81.7)

591 (79.64)

Divorced

91 (8.24)

32 (8.81)

59 (8.02)

Separated

26 (2.35)

8 (2.33)

18 (2.38)

Never married

88 (7.96)

23 (6.46)

65 (8.75)

Other

12 (1.09)

3 (0.7)

Household size (M [SD])
Household income

Employment status

4.17 (1.39)

4.28(1.58)

136 (12.31)

43 (11.76)

93 (12.57)

$25,000-$49,999

215 (19.46)

65 (17.94)

150 (20.22)

$50,000-$99,999

361 (32.67)

109 (29.91)

252 (33.93)

> $100,000

394 (35.66)

147 (40.4)

247 (33.28)

Working (paid employee or
self-employed)

884 (80.0)

281 (77.31)

603 (81.23)

816

4.29 (1.31)

Not working (temporary layoff
OR looking for work)

57 (5.16)

18 (4.9)

39 (5.3)

Retired

25 (2.26)

12 (3.31)

13 (1.73)

Disabled

36 (3.26)

14 (3.77)

22 (2.94)

104 (9.41)

39 (10.71)

65 (8.8)

≤ 12 grade (did not graduate
high school)

64 (5.79)

25 (6.95)

39 (5.2)

High school graduate or GED

341 (30.86)

102 (28.23)

239 (32.22)

Some college

247 (22.35)

72 (19.94)

175 (23.64)

40 (11)

< .001
.045
.104

.071
.637

9 (1.22)

< $25,000

Not working (other)
Highest level of
education

41.55 (7.74)

Male

other, Non-Hispanic
Residence

44.03 (7.56)

Associate’s degree

98 (8.87)

58 (7.84)

Bachelor’s degree

200 (18.1)

64 (17.75)

136 (18.28)

Master’s degree or higher

154 (13.94)

59 (16.12)

95 (12.81)

.931
.141

.315

.120
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Table 1
Socio-demographic and Healthcare-related Characteristics of Total Study Sample (N=1105)
and by Child’s HPV Vaccination Status
Variable

Level

Total sample

HPV vaccinated

(N=1105)

child
(N=363)

HPV un-vaccinated child

p-value

(N=742)

CHARACTERISTICS OF CHILD
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Age (years)

Gender

9

135 (12.26)

2 (0.57)

133 (18.03)

10

117 (10.63)

1 (0.36)

116 (15.74)

11

112 (10.17)

25 (6.86)

87 (11.81)

12

119 (10.81)

36 (9.98)

83 (11.19)

13

122 (11.08)

63 (17.35)

59 (7.99)

14

123 (11.17)

58 (16.06)

65 (8.79)

15

99 (8.99)

53 (14.8)

46 (6.27)

16

150 (13.62)

69 (18.98)

81 (10.95)

17

122 (11.08)

54 (15.04)

68 (9.23)

Male

548 (49.59)

174 (48.55)

374 (50.43)

Female

550 (49.77)

183 (51.15)

367 (49.53)

1 (0.09)

1 (0.3)

0 (0.00)

Public insurance

441 (40.38)

149 (41.66)

292 (39.69)

Private insurance

592 (54.21)

194 (54.24)

389 (52.92)

69 (6.32)

15 (4.11)

54 (7.39)

510 (46.2)

343 (94.57)

167 (22.58)

Other
Health insurance
coverage

No insurance
Received healthcare
Yes (vs all others)
provider recommendation
for the HPV vaccine

< .001

.486

.110

< .001

Note.
Totals may not sum to 1105 for all variables due to missing data.

3, 10, 12) did not load strongly onto either factor;
we dropped them from the subsequent CFA.
Both the original 13-item HPV-KQ and the
2-factor solution that emerged from the EFA fit
the data well, based on fit indices in the CFA
(Table 3).51 We used the chi-square goodness-of-fit
test to examine model fit. The 2-factor solution fit
the data better than the original 13-item scale and
a constrained one-factor solution consisting of the
10-items with strong factor loadings. Cronbach’s
alpha indicated that the original 13-item HPV-KQ
had high internal consistency (α = 0.87), as did
the 2 derived factors (Factor 1 α = 0.84; Factor 2
α = 0.82).
Predictive Validity Analyses
Table 4 displays the number and percentage of

parents who correctly answered each HPV-KQ
item, as well as differences across individual items
and total knowledge scores for parents of vaccinated
versus unvaccinated adolescents. Percentages of
correct responses varied widely across individual
items; only 20.2% of participants answered item
10 correctly (“Nearly all sexually active people will
become infected with HPV at some point”), whereas
80.1% of participants answered item 2 correctly
(“HPV can cause cervical cancer in women”). In
addition to item 10, other ‘low-scoring’ items
included item 3 (“HPV can cause cancer in areas
such as the head and neck” 21.2% correct), item
5 (“HPV can cause genital warts” 45.5% correct),
and item 13 (“The HPV vaccine is most effective
if given to people who have not yet started having
sex” 44.4% correct).
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Table 2
Results of Exploratory Factor Analysis for the 13-item HPV-KQ
Factor loadings

Uniqueness/
Unique
variances
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Item

Factor 1

Factor 2

1. Only women can get infected with HPV (False)a

0.212

0.782*

0.344

2. HPV can cause cervical cancer in women (True)

0.481*

0.421

0.591

3. HPV can cause cancer in areas such as the head and neck
(True)

0.353

0.056

0.872

4. HPV causes cancer in women only (False) a

0.188

0.688*

0.492

5. HPV can cause genital warts (True)

0.591*

0.140

0.632

6. A person could have HPV for many years without knowing it
(True)

0.618*

0.402

0.457

7. HPV is transmitted through sex (True)

0.669*

0.315

0.454

8. Most people infected with HPV have visible signs or symptoms
of the infection (False)a

0.451*

0.417

0.623

9. A person’s chances of getting HPV increase with the number
of sexual partners they have (True)

0.682*

0.264

0.465

10. Nearly all sexually active people will contract HPV at some
point (True)

0.374

0.111

0.848

11. The HPV vaccine is only recommended for girls (False) a

0.189

0.775*

0.363

12. Full protection against HPV requires more than 1 dose of the
vaccine (True)

0.370

0.337

0.750

13. The HPV vaccine is most effective if given to people who
have not yet started having sex (True)

0.575*

0.175

0.639

4.59

0.89

-

Eigenvalue of
factors without
rotation

-

Percentage
of variance
explained by
factors

-

83.8

16.2

-

Note.
a

Reverse-coded items

Parents with vaccinated adolescents displayed
significantly greater knowledge across all items when
compared to parents of unvaccinated adolescents
(range of p = .04 to p < .001). Parents of vaccinated
adolescents displayed high levels of knowledge
about HPV causing cervical cancer (88.0% correct),
about HPV infecting both men and women
(90.4% correct), about the possibility of asymptomatic infection (80.6% correct), and about the
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recommendation that both girls and boys receive
the HPV vaccine (81.2% correct). Parents of
vaccinated adolescents scored higher than parents
of unvaccinated adolescents on the original
13-item HPV-KQ (M = 8.6 vs M = 6.4, p < .001),
on Factor 1 (M = 4.8 versus M = 3.9, p < .001),
and on Factor 2 (M = 2.0 versus M = 1.8, p < .001).
The 3 items that did not load onto the 2-factor
solution (items 3, 10, 12) were notable in that they

Harrison et al

Table 3
Confirmatory Factor Analysis for One-factor and 2-factor Solutions for the HPV-KQ
Factor Solution

Items

N of
items

One factor solution
(13-item constrained
model)

13

One factor solution
(10-item constrained
model)a

10

1-13

Standardized
root mean
square residual
(SRMR)

χ2
p-value

Goodness
of Fit Index
(GFI)

Adjusted GFI
(AGFI)

< .0001

0.834

0.768

0.072

0.121

< .0001

0.835

0.758

0.071

0.123

< .0001

0.916

0.867

0.051

0.087

Root mean
square error of
approximation
(RMSEA)

1,2,4,5,
6,7,8,9,
11,13
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Factor 1
(2,5,6,7,
Two factor solution
(Factor 1 + Factor 2)

10

8,9,13)
+
Factor 2
(1,4,11)

Note.
Recommended thresholds for acceptable model fit indices: Goodness of Fit Index (GFI): > 0.90;51 Adjusted
Goodness-of-Fit Index (AGFI): > 0.85;51 Standardized root mean square residual (SRMR): < 0.08;31,33 Root mean square
error of approximation (RMSEA): < 0.0640
a
Contains all items with strong factor loadings (> 0.45) in the EFA

were highly missed items. Only 21.2% of participants correctly answered item 3 (“HPV can cause
cancer in areas such as the head and neck”) and
only 20.2% correctly answered item 10 (“Nearly
all sexually active people will become infected with
HPV at some point”). Item 12 yielded the largest
difference between parents of vaccinated and
unvaccinated adolescents, with 73.9% of parents
of vaccinated adolescents correctly reporting that
HPV vaccination requires more than one dose,
compared to only 38.6% of parents of unvaccinated
adolescents (p < .001).
Table 5 shows abbreviated results of the multi
variable regression models assessing whether
parental HPV knowledge predicted adolescent
uptake of HPV vaccination (≥ 1 dose). Complete
model data are found in Supplementary Tables 1
and 2. We ran separate models for the full sample
(Model 1; N=1105), for parents who had never
received a provider recommendation for HPV
vaccination (Model 2; N=593), and for parents who
had received a provider recommendation (Model 3;
N=510). As expected, parental performance on

the HPV-KQ predicted adolescent uptake of HPV
vaccination, when controlling for key covariates
(eg, adolescent race/ethnicity, age, gender, parent
employment status, etc). Specifically, parents’
scores on the 13-item HPV-KQ and parents’ scores
on Factor 2 predicted adolescent vaccine uptake in
the full sample (p < .001 and p = .008, respectively)
and among parents who reported having received a
provider recommendation for HPV vaccination
(p = .01 and p = .01, respectively). (p < .001, p = .008,
respectively). Parental knowledge scores for Factor 1
did not significantly predict adolescent vaccination
uptake in any group (p > .05).
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DISCUSSION
Evidence from this study supports the use of the
HPV-KQ for evaluating knowledge of HPV and
HPV vaccination among parents in the US South.
The scale has strong internal consistency and also
offers other benefits, including accessibility (ie, 5th
grade reading level) and brevity. Most importantly,
the HPV-KQ captures key information on HPV
transmission, sequelae, and prevention. It reflects
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Table 4.
Differences among Parents (N=1105) in Individual Item Responses and Total Knowledge
Scores by Child’s HPV Vaccination Status, for Total Scale and Derived Factors
HPV-KQ Item

Factor

Parents’ correct responses
N (%)
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Total sample
(N=1105)

Parent of HPV
vaccinated child
(N=363)

Parent of HPV
unvaccinated
child

(N=742)

1. Only women can get infected with HPV
(False)a

2

844 (76.38)

328 (90.43)

516 (69.6)

< .001

2. HPV can cause cervical cancer in women
(True)

1

885 (80.09)

320 (88.03)

565 (76.12)

< .001

3. HPV can cause cancer in areas such as the
head and neck (True)

-

234 (21.18)

96 (26.37)

138 (18.61)

.003

4. HPV causes cancer in women only (False)a

2

677 (61.27)

271 (74.74)

406 (54.76)

< .001

5. HPV can cause genital warts (True)

1

503 (45.52)

195 (53.69)

308 (41.48)

< .001

6. A person could have HPV for many years
without knowing it (True)

1

804 (72.76)

293 (80.63)

511 (68.89)

< .001

7. HPV is transmitted through sex (True)

1

677 (61.27)

257 (70.83)

420 (56.67)

< .001

8. Most people infected with HPV have visible
signs or symptoms of the infection (False)a

1

577 (52.22)

236 (64.95)

341 (45.94)

< .001

9. A person’s chances of getting infected with
HPV increase with the number of sexual partners they have (True)

1

706 (63.89)

265 (72.93)

441 (59.48)

< .001

10. Nearly all sexually active people will become
infected with HPV at some point (True)

-

223 (20.18)

86 (23.74)

137 (18.43)

.04

11. The HPV vaccine is only recommended for
girls (False)a

2

701 (63.44)

295 (81.19)

406 (54.72)

< .001

12. Full protection against HPV requires more
than 1 dose of the vaccine (True)

-

555 (50.23)

268 (73.88)

287 (38.64)

< .001

13. The HPV vaccine is most effective if given to
people who have not yet started having sex
(True)

1

491 (44.43)

197 (54.2)

294 (39.56)

<.001

Total Knowledge Scores
Mean (SD)

a

p-value

p-value

13-item HPV-KQ

7.13 (3.16)

8.56 (3.02)

6.43 (3.91)

< .001

HPV-KQ Factor 1 (7 items)

4.20 (2.37)

4.85 (2.02)

3.88 (2.47)

< .001

HPV-KQ Factor 2 (3 items)

2.01 (1.20)

2.46 (0.92)

1.79 (1.26)

< .001

Reverse-coded items

up-to-date information on HPV and HPV vaccination such as the need for multiple doses of the
vaccine, recommendations that both boys and girls
be vaccinated, and evidence that the vaccine is
most effective when received early in adolescence
(ie, before sexual debut). These are important pieces
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of knowledge given the large numbers of parents
who delay initiation of the HPV vaccine series for
their adolescent, fail to complete the series, or fail
to initiate entirely. The inclusion of several items
focused on boys and men in the HPV-KQ is also
important, as males have been underrepresented in

Harrison et al

Table 5
Multivariable Logistic Regression Models Examining the Association between Parent
Performance on the HPV-KQ and Adolescent HPV Vaccine Uptake, by Provider
Recommendation for HPV Vaccination
Outcome variable: Adolescent uptake of ≥ 1 dose of the HPV vaccine
Model 1

Model 2

Model 3

All parents (N=1105)

Parents reporting no provider
recommendation (N=593)

Parents reporting provider
recommendation (N=510)

OR
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VARIABLES

(95% CI)

p value

OR
(95% CI)

p value

OR

p value

(95% CI)

HPV-KQ (13 items)

1.07
(1.03,1.11)

< .001

1.06
(0.98,1.15)

.12

1.08
(1.02,1.14)

.01

HPV-KQ Factor 1 (7 items)

0.95
(0.87,1.04)

0 .25

0.84
(0.68,1.04)

.11

0.98
(0.9,1.06)

.58

HPV-KQ Factor 2 (3 items)

1.37
(1.09,1.74)

1.67
(0.91,3.07)

.10

1.32
(1.06,1.64)

.01

.008

Note.
See Supplementary Tables 1 and 2 for full models. Models for HPV-KQ Factor 1 and HPV-KQ Factor 2 are fitted jointly.
Adolescent covariates included in the models: race/ethnicity, gender, age, school type, travel time to healthcare provider, health
care visit in past year. Parent covariates included in the models: employment status.

HPV-related research and vaccination campaigns.
In addition, the 13-item HPV-KQ includes an
item about head and neck cancers, an important
new area of emphasis given observed increases in
oropharyngeal cancers. Given these strengths, the
HPV-KQ likely is useful in capturing information
about individuals’ knowledge of HPV to develop
public health campaigns and programming to combat vaccine misinformation and vaccine hesitancy
among US parents.
In a sample of more than 1100 parents from 13
southern states, respondents, on average, answered
only 7 of 13 knowledge questions correctly. Several
HPV-KQ items were missed by large numbers of
participants, signaling potential gaps in parental
HPV knowledge. Few parents were familiar with
the widespread prevalence of HPV among sexually
active unvaccinated adults or the causal role of
HPV in head and neck cancers. Fewer than half
of parents correctly answered an item about HPV
causing genital warts. The need for early initiation
of HPV vaccination was not widely understood.
Future public health campaigns to target these
aspects of HPV-related knowledge may be useful.
Understanding that nearly all sexually active
unvaccinated individuals will acquire HPV at some

point may help convince parents of the importance
of timely vaccination and reduce HPV-related stigma.
In our study, parents of vaccinated adolescents
demonstrated higher HPV knowledge on the
HPV-KQ than parents of unvaccinated adolescents,
consistent with prior findings using other HPV
knowledge scales.22 Parents of vaccinated adolescents
outperformed parents of unvaccinated adolescents
on all items, including items that assessed prevalence,
symptoms, HPV-associated cancers, sexual transmission of HPV, potential for dormancy, and vaccination recommendations. Parental HPV knowledge
may increase vaccination intentions and use;
conversely, the vaccination process also may cause
increases in parents’ knowledge. Additional research
is needed to understand the complex relationship
between knowledge, vaccination intentions, and
vaccination behaviors. Prospective studies would
be especially helpful to understand temporal aspects
of these relationships. In addition, findings support
the predictive validity of the scale, as parental performance on the HPV-KQ predicted adolescent
vaccination status when controlling for key parental
and adolescent covariates.
Because scientific understanding and clinical
recommendations for HPV vaccination change
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over time, updating or creating new knowledge
scales periodically is important. In addition, the
target audience of a knowledge scale, both in terms
of the development process and psychometric
validation, is critical. The HPV-KQ was intended
for use with parents of adolescents in the US.
Its readability level enables it to be administered
to adolescents as well, although future validation
studies with this age group are needed. With recent
changes in vaccination recommendations for adults
ages 27 through 45 years (ie, shared clinical
decision-making), there is also a need to investigate
knowledge among adults who are considering
vaccination for themselves. Some knowledge items
on the HPV-KQ assess areas that may not be
relevant for adults considering HPV vaccination
(eg, initiation prior to sexual debut, child vaccination
recommendations). Expansion or modification of
the scale may be useful for this population.
A final important consideration is whether
researchers and clinicians should adopt the full
13-item HPV-KQ or the 2-factor solution that
emerged from EFA. Whereas the 2-factor solution
demonstrated a superior model fit, the original 13item scale fit the data relatively well and allows for
the inclusion of important items such as HPV’s
causal role in head and neck cancers and the widespread prevalence of HPV. Importantly, the 3 items
that did not load strongly onto either of the 2 factors during EFA were items that were missed frequently by participants. These items may represent
gaps in knowledge, and, with appropriate justification, may be beneficial to include in future studies
utilizing the HPV-KQ.
Strengths of the current study include that the
development of the HPV-KQ was tailored to
address gaps in existing scales, and the scale includes
multiple items that address the HPV vaccine’s role
in cancer prevention. In addition, the scale was
validated for a large and diverse sample of parents
in the southern US, a region disproportionately
burdened by HPV-associated cancers.52 This study
also included parents of adolescents across a broad
age range (9 to 17 years), including large numbers
of both vaccinated and unvaccinated youth.
Limitations to this study include the use of only
parents from the southern US. Although the parent
sample was large (N=1105), drawn from 13 states,
and diverse in terms of gender, race, and ethnicity,
future validation efforts may wish to expand to
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other US regions. In addition, parental report of
their children’s vaccination status was not confirmed by providers or state registries. Limitations
to our study also included how parental HPV
knowledge was conceptualized. The HPV-KQ included response options of “true,” “false,” and “I
don’t know.” For the current study, responses of
“false” and “I don’t know” were grouped together
and considered to represent “lack of knowledge”
(ie, scored as 0). Future studies may wish to analyze
these responses separately to determine whether
there are key differences in lack of knowledge (ie, “I
don’t know” responses) versus misinformation (ie,
“false” responses).
In terms of limitations regarding psychometric
findings, it should be noted that whereas Factor
2 appeared to capture gender-relevant knowledge
about HPV, all Factor 2 items were “false” items.
Thus, there is a possibility that Factor 2 is an artifact
of response patterns (eg, failure to read the wording
closely, confusion over how to answer false items,
etc). This concern is mitigated somewhat by the fact
that parents of vaccinated adolescents performed
better than parents of unvaccinated adolescents on
all items, regardless of whether they were “true” or
“false.”
In addition, we found differences in the predictive
value of the full HPV-KQ, Factor 1, and Factor 2.
Specifically, multivariable logistic regression modeling
showed that parents’ performance on the 13-item
scale and on Factor 2 predicted adolescent vaccination for both the full sample and for parents who
had received a provider recommendation for HPV
vaccination, with higher parental knowledge associated with increased likelihood of vaccination when
controlling for important covariates. However,
performance on the 7-item Factor 1 did not predict
adolescent vaccination status. This may reflect
the importance of gender-based HPV knowledge;
all Factor 2 items addressed that HPV and HPV
vaccination impact all genders. Communication
and health messaging that stress the importance
of HPV vaccination among males continues to be
critical, especially given the barriers to male vaccination that have been identified.53 Parents with
knowledge about the universal recommendations
for vaccination for boys and girls also may hold
less stigma about HPV vaccination, as they may
perceive HPV vaccination as a routine part of well
child visits for boys and girls alike.
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With initial evidence supporting the use of the
HPV-KQ to measure HPV knowledge, a number
of future directions exist. An important extension
will be to conduct additional validation studies,
including comparing parent performance on the
HPV-KQ with existing HPV knowledge measures. Additional validation studies that compare
parent performance on the HPV-KQ to existing
HPV knowledge scales would be useful. In addition, administering the HPV-KQ to adolescents
and young adults would be an important extension.
Adolescents, particularly early and middle adolescents, often have been excluded from research on
vaccine decision-making.53-55 Investigating what
adolescents know about HPV and the HPV vaccine
and identifying effective ways to provide developmentally appropriate information would be worthy
goals of future research. Use of the scale to explore
whether there are socio-demographic differences in
knowledge (eg, gender, race, and ethnicity-related
differences; differences across geographic areas) also
may be useful in efforts to target particular groups
or places for HPV information campaigns. In
addition, greater understanding is needed of the role
that HPV knowledge plays in HPV decision-making.
Innovative mobile interventions are under development56,57 that use technology to increase HPV
knowledge and promote positive attitudes toward
vaccination. Robust knowledge scales will continue to play an important role in measuring changes
in HPV knowledge as part of discrete interventions.
Knowledge scales also are critical to measure changes in HPV knowledge over time as we continue to
make progress towards high HPV vaccination
coverage and the eradication of HPV-associated cancers.

beginning of the Web-based survey, communicated
the survey purpose and the contact information of
the study’s principal investigator. Responses to all
survey questions beyond an initial eligibility screen
were optional.
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Outcome variable: Adolescent uptake of > 1 dose of the HPV vaccine

Parental HPV
knowledge

Total Score on
13-item HPV-KQ

Adolescent’s race and
ethnicity

Hispanic

Non-Hispanic
other
Adolescent gender

All parents
(N=1105)

Parents reporting
no provider
recommendation
(N=593)

Parents reporting
provider
recommendation
(N=510)

p value

1.22
(1.17,1.27)

< .001
.36

(0.67,2.96)
1.46

.27

(0.74,2.87)
0.8

.24

(0.56,1.16)
1.14

(female vs male or other)

.41

(0.84,1.54)
1.45

In years

(1.36,1.53)
Home/Online
school vs Public
School

(0.1,0.49)

Other School vs
Public School

(0.6,2.17)

Parent’s employment
status

Working vs Not
working or other

(0.22,0.87)

Travel time to regular
healthcare provider

< 15 minutes vs >
15 minutes

(1.33,2.15)

Healthcare visit for
adolescent in past 12
months

Yes vs No/Other
Degrees of
Freedom
-2 Log L
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Model 3

1.41

(vs white, non-Hispanic) Non-Hispanic
black or African-American

Adolescent’s type of
school

Model 2

OR
(95% CI)

Predictor Variables

Adolescent’s age

Model 1

0.22

< .001
< .001

1.14

.68

0.44
1.69

.02
< .001

2.32
(1.29,4.16)

.005

OR
(95% CI)

p value

1.06

.12

(0.98,1.15)
1.01

.98

(0.34,3.01)
2.25

.05

(1.02,4.96)
1.3

.74

(0.27,6.31)
1.91

.19

(0.73,4.98)
1.27
(1.11,1.45)
0

< .001
< .001

(<0.001,
<0.001)
2.13

.31

(0.5,9.16)
0.59
(0.18,1.99)
1.83
(0.72,4.63)
0.53

.40
.20
.51

(0.08,3.5)

OR
(95% CI)
1.08
(1.02,1.14)
1.35
(0.6,3.02)
1.52
(0.55,4.16)
0.55

p value
.01
.47
.42
.05

(0.31,1)
0.64
(0.47,0.86)
1.34
(1.27,1.41)
0.15
(0.06,0.38)
1.34
(0.7,2.57)
0.29
(0.14,0.61)
2
(1.29,3.09)
1.75
(0.71,4.32)

11

11

11

1099.2

153.9

560.9

.003
< .001
< .001
.37
.001
.002
.23
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-2 Log L

Degrees of Freedom

Yes vs No/Other

< 15 minutes vs > 15 minutes

Healthcare visit for
adolescent in past 12 months

Working vs Not working or other

2.51 (1.54,4.07)

1.69 (1.36,2.09)

0.45 (0.23,0.87)

1.17 (0.62,2.2)

Other School vs Public School

Travel time to regular
healthcare provider

0.22 (0.11,0.47)

Home/Online school vs Public
School

Adolescent’s type of school

12
1101.9

< .001

< .001

.02

.628

< .001

< .001

.18

.49

.09

.86

.10

.11

p value

0.56 (0.1,3.24)

1.73 (0.67,4.49)

0.64 (0.19,2.19)

2.08 (0.45,9.54)

150.4

12

.51

.26

.48

.35

0 (<0.001, <0.001) < .001

1.25 (1.11,1.4)

< .001

1.44 (1.35,1.54)

1.66 (0.39,7.08)
2.07 (0.72,5.99)

In years

Parent’s employment status

1.1 (0.38,3.16)
2.16 (0.88,5.28)

.19

.6

.35

.37

1.67 (0.91,3.07)

.001

OR (95% CI)
0.84 (0.68,1.04)

.15

p value

1.23 (0.9,1.68)

0.9 (0.6,1.34)

Adolescent’s age

Adolescent gender
(female vs male or other)

1.38 (0.7,2.75)

Non-Hispanic black or
African-American
Non-Hispanic other

1.39 (0.68,2.83)

Hispanic

Adolescent’s race and ethnicity
(vs white, non-Hispanic)

1.63 (1.21,2.18)

3-item HPV-KQ Factor 2

Parental HPV knowledge
factor 2

1.1 (0.97,1.26)

7-item HPV-KQ Factor 1

OR (95% CI)

Parents reporting no
provider recommendation
(N=593)

All parents
(N=1105)

Parental HPV knowledge
factor 1

Predictor Variables

Model 2

Model 1

Outcome variable: Adolescent uptake of > 1 dose of the HPV vaccine

Key knowledge variable: 13-item HPV-KQ

1.79 (0.73,4.38)

2.03 (1.36,3.03)

0.29 (0.13,0.62)

1.41 (0.74,2.7)

0.15 (0.06,0.38)

1.34 (1.27,1.42)

0.71 (0.53,0.94)

0.59 (0.34,1.03)

1.46 (0.53,4.02)

1.27 (0.6,2.72)

1.32 (1.06,1.64)

0.98 (0.9,1.06)

OR (95% CI)

560.2

12

.20

.001

.001

.3

< .001

< .001

.02

.06

.46

.53

.01

.58

p value

Parents reporting provider
recommendation
(N=510)

Model 3

Supplemental Table 2
Full Regression Models Predicting Adolescent Uptake of ≥ 1 dose of the HPV Vaccine by 7-item HPV-KQ Factor 1 Score and
3-item HPV-KQ Factor 2 Score for Total Sample and by Provider Recommendation Status
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